Family-controlled Boehringer Ingelheim GmbH has bought privately held Amal Therapeutics SA an academic-based biotech whose proprietary technology promises to significantly enrich the German pharma’s cancer immunology portfolio with novel cancer vaccines.
“We made this acquisition because we were really impressed by the quality of science at AMAL, by its unique vaccine platform, called KISIMA, and by their lead asset, ATP128, which is directly in the target indication that is of high interest to our oncology group strategically,” Scott
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?